Drug therapy development
Our therapeutics
Avenzoar specializes in developing small molecule therapeutics for cancer. Our lead drug, AP-001 (Metavert™), is a dual inhibitor small molecule designed to prevent cancer growth and metastasis. AP-001 has the potential to revolutionize cancer therapy.
Pre-clinical results | Trials
AP-001 is an innovative anti-cancer drug that targets two pro-cancer pathways simultaneously. Pre-clinical results show significant prevention of pancreatic cancer growth and metastasis with no significant toxicity. Clinical trials for pancreatic cancer patients are set to begin in 2025, with potential trials for ovarian and metastatic liver cancer to follow.
Pancreatic Cancer
Survival rates for pancreatic cancer are notably low, with only 12% of patients surviving beyond five years post-diagnosis, largely due to late-stage diagnoses. Surgical removal of tumors is feasible in less than 20% of cases.
Current treatments primarily involve chemotherapy and radiation therapy, aiming to control the disease and improve patient quality of life.
12th
495k
466k
64k
12k
Ovarian Cancer
Five-year ovarian cancer survival rates vary between countries. For example, in more developed countries, current rates range from 36% to 46%. However, in some countries, the figure is much lower.
The five-year survival rate is 51%, falling well below that for other cancers. The first-line treatment for ovarian cancer typically includes surgery, followed by chemotherapy with platinum-based agents and a taxane.
8th
324k
207k
19k
51%
on Pancreatic Cancer
Hirshberg Foundation for Pancreatic Cancer Research
Driving impact Together
Our rigorous clinical development program is designed to meet the highest standards of regulatory scrutiny.
Avenzoar Pharmaceuticals is working closely with regulatory bodies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to ensure that AP-001 meets all regulatory requirements for approval.
New drugs capable of targeting more than one oncogenic pathway may be one way to improve patient outcomes. This study characterizes the effectiveness of Metavert a first-in-class dual inhibitor of GSK3-β and histone deacetylase in treating PDAC
Metavert SynergisesWe are actively seeking collaboration opportunities with major pharmaceutical companies to bring AP-001 to patients. Engaging with industry leaders will enable us to leverage their manufacturing, distribution, and training capabilities to ensure that AP-001 reaches the pancreatic cancer patients who need it most.